中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

50 records (took 0.035 seconds)

    Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
    21.
    发明申请
    Combinatorial DNA library for producing modified N-glycans in lower eukaryotes 有权
    用于在低等真核生物中生产修饰的N-聚糖的组合DNA文库

    公开(公告)号：US20090209024A1

    公开(公告)日：2009-08-20

    申请号：US12156936

    申请日：2008-06-05

    Applicant: Tillman U. Gerngross ,  Stefan Wildt ,  Byung-Kwon Choi ,  Juergen Hermann Nett ,  Piotr Bobrowicz ,  Stephen R. Hamilton ,  Robert C. Davidson

    Inventor： Tillman U. Gerngross ,  Stefan Wildt ,  Byung-Kwon Choi ,  Juergen Hermann Nett ,  Piotr Bobrowicz ,  Stephen R. Hamilton ,  Robert C. Davidson

    IPC: C12N1/19 ,  C12N1/15

    CPC classification number: C12P21/005 ,  C07K14/47 ,  C12N9/1051 ,  C12N15/1082 ,  C12N15/79

    Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.

    Abstract translation: 本发明涉及具有修饰的寡糖的真核宿主细胞，其可以通过异源表达一组糖基转移酶，糖转运体和甘露糖苷酶进一步修饰，以成为用于产生哺乳动物例如人治疗性糖蛋白的宿主菌株。 本发明提供核酸分子和组合文库，其可用于成功靶向和表达哺乳动物酶活性，例如参与糖基化的真核宿主细胞中的细胞内区室的那些。 该方法提供了可用于表达和靶向参与糖基化的任何所需基因的工程化宿主细胞。 建立或选择具有修饰寡糖的宿主细胞。 在工程化宿主细胞中制备的N-聚糖具有Man5GlcNAc2核心结构，然后可以通过异源表达一种或多种酶，例如糖基转移酶，糖转运蛋白和甘露糖苷酶来进一步修饰，以产生人样糖蛋白。 为了生产治疗性蛋白质，该方法可适用于工程化可能获得任何所需糖基化结构的细胞系。

    Production of modified glycoproteins having multiple antennary structures
    23.
    发明申请
    Production of modified glycoproteins having multiple antennary structures 失效
    具有多个触角结构的修饰的糖蛋白的生产

    公开(公告)号：US20070037248A1

    公开(公告)日：2007-02-15

    申请号：US10546101

    申请日：2004-02-20

    Applicant: Piotr Bobrowicz ,  Stephen Hamilton ,  Tillman Gerngross ,  Stefan Wildt ,  Byung-Kwon Choi ,  Juergen Nett ,  Robert Davidson

    Inventor： Piotr Bobrowicz ,  Stephen Hamilton ,  Tillman Gerngross ,  Stefan Wildt ,  Byung-Kwon Choi ,  Juergen Nett ,  Robert Davidson

    IPC: C07K14/47 ,  C07H21/04 ,  C12P21/06 ,  C12N1/18 ,  C12N15/74

    CPC classification number: C12P21/005 ,  C12N9/1051

    Abstract: The present invention relates to eukaryotic host cells, especially lower eukaryotic host cells, having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar and sugar nucleotide transporters to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII, GnTIV, GnTV, GnT VI or GnTIX activity, which produce bisected and/or multiantennary N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar, sugar nucleotide transporters, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.

    Abstract translation: 本发明涉及具有修饰的寡糖的真核宿主细胞，特别是较低的真核宿主细胞，其可以通过异源表达一组糖基转移酶，糖和糖核苷酸转运蛋白进一步修饰，以成为用于产生哺乳动物的宿主菌株， 人类治疗糖蛋白。 该方法提供了可用于表达和靶向参与糖基化的任何所需基因的工程化宿主细胞。 制备或选择具有修饰的脂质连接寡糖的宿主细胞。 在工程化宿主细胞中制备的N-聚糖表现出GnTIII，GnTIV，GnTV，GnT VI或GnTIX活性，其产生二等分和/或多元N-聚糖结构，并且可以通过异源表达一种或多种酶，例如糖基转移酶 ，糖，糖核苷酸转运蛋白，以产生人样糖蛋白。 为了生产治疗性蛋白质，该方法可适用于工程化可能获得任何所需糖基化结构的细胞系。

    Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
    25.
    发明申请
    Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform 审中-公开
    主要包含Man5GlcNAc2糖型的免疫球蛋白

    公开(公告)号：US20060024304A1

    公开(公告)日：2006-02-02

    申请号：US11187196

    申请日：2005-07-21

    Applicant: Tillman Gerngross ,  Huijuan Li ,  Stefan Wildt

    Inventor： Tillman Gerngross ,  Huijuan Li ,  Stefan Wildt

    IPC: A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C40B40/10

    CPC classification number: C07K16/00 ,  C07K16/2896 ,  C07K2317/41 ,  C40B40/10

    Abstract: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man5GlcNAc2.

    Abstract translation: 本发明涉及在赋予特异性效应子功能的免疫球蛋白糖蛋白上具有主要N-聚糖结构的免疫球蛋白糖蛋白组合物。 另外，本发明涉及包含具有特定富集的N-聚糖结构的抗体的药物组合物，其中所述N-聚糖结构是Man 5'CaccNAc 2。

Patent Agency Ranking